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Abstract
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Endoplasmic reticulum (ER) stress responses through the IRE-1/XBP-1 pathway are required for
the function of STING (TMEM173), an ER-resident transmembrane protein critical for
cytoplasmic DNA sensing, interferon production and cancer control. Here we show that the IRE-1/
XBP-1 pathway functions downstream of STING and that STING agonists selectively trigger
mitochondria-mediated apoptosis in normal and malignant B cells. Upon stimulation, STING was
degraded less efficiently in B cells, implying that prolonged activation of STING can lead to
apoptosis. Transient activation of the IRE-1/XBP-1 pathway partially protected agonist-stimulated
malignant B cells from undergoing apoptosis. In Eμ-TCL1 mice with chronic lymphocytic
leukemia, injection of the STING agonist 3′3′-cGAMP induced apoptosis and tumor regression.
Similarly efficacious effects were elicited by 3′3′-cGAMP injection in syngeneic or
immunodeficient mice grafted with multiple myeloma. Thus, in addition to their established ability
to boost anti-tumoral immune responses, STING agonists can also directly eradicate malignant B
cells.
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In mammalian cells, the presence of double-stranded DNA in the cytoplasm is a danger
signal of infections or cell anomalies. These bacterial, viral or self DNA can be recognized
by a cytoplasmic DNA sensor, cyclic GMP-AMP synthase (cGAS). Upon binding to DNA,
cGAS generates 2′3′-cGAMP as an endogenous ligand to activate the stimulator of
interferon gene (STING) (1–5). Bacteria-produced cyclic dinucleotides, c-di-AMP, c-di-
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GMP and 3′3′-cGAMP, as well as the unnatural 2′2′-cGAMP can also bind to and activate
STING (5–9). Different from Toll-like receptors (TLRs) which are found either on the cell
surface or in the endosomes, STING is an endoplasmic reticulum (ER)-resident protein
(10,11). Activation of STING by its agonists can lead to the exit of STING from the ER into
the secretory pathway (i.e., the Golgi apparatus and vesicles), in which the phosphorylation
of STING occurs, leading to the phosphorylation of interferon regulatory factor 3 (IRF3) to
allow for the production of type I interferons (IFNα and IFNβ) to stimulate the immune
system and restore health (10–13). The agonist-bound STING is eventually destructed in the
endosomes.

Author Manuscript

Since STING is a critical mediator for the production of interferons, agonists of mouse
STING like c-di-GMP and c-di-AMP have been proposed as adjuvants to elicit potent
immune response (14–16). In addition, 2′3′-cGAMP was shown to aid in radiation-based
cancer therapy (17). DMXAA (5,6-dimethylxanthenone-4-acetic acid) is a potent chemical
compound which can shrink solid tumors in mice by disrupting tumor vasculature and
boosting the immune system by producing cytokines (18–20). CMA (10-carboxymethyl-9acridanone) is an anti-viral compound that can induce type I interferons (21,22). Both
DMXAA and CMA were recently co-crystallized with STING (9,23,24). However, it is
unclear whether these STING-binding cyclic dinucleotides and chemical compounds
(DMXAA and CMA) can directly exert cytotoxicity in tumor cells. The potency of cyclic
dinucleotides, DMXAA and CMA in activating STING to produce type I interferons has
also not been compared side by side using intact cells.
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The lumen of the ER contains chaperone proteins such as HSP70-like GRP78/BiP, HSP90like GRP94, protein disulfide isomerase (PDI), and lectin-binding calreticulin and calnexin
to facilitate the folding, assembly and quality control of integral membrane proteins and
secretory proteins. The ER is also equipped with sensor molecules that have the capability in
activating the ER stress response upon stress conditions (25,26). One of these sensor
molecules is IRE-1. IRE-1 is an ER resident transmembrane protein that contains an ER
stress sensor domain facing the lumen of the ER, and this luminal domain is linked to its
cytoplasmic kinase/RNase domain by a transmembrane domain. Upon activation, IRE-1
undergoes oligomerization and autophosphorylation to assemble a functional RNase that
specifically splices 26 nucleotides from the mature XBP-1 mRNA in mammalian cells (27–
30). Such an excision followed by the subsequent ligation of the mRNA leads to a reading
frame shift in translation, and the spliced XBP-1 mRNA encodes a larger 54-kDa
transcription factor, XBP-1s, in mammalian cells (29). XBP-1s is responsible for
upregulating the synthesis of lipids and chaperones, contributing to the restoration of a
homeostatic ER (31–33). Stimulations of B cells with the TLR4 ligand (lipopolysaccharides,
LPS) or TLR9 ligand (CpG) activate the IRE-1/XBP-1 pathway to support B cell growth and
differentiation, as evidenced by robust B cell proliferation and antibody production (34–36).
The lack of IRE-1 or XBP-1 blocks the antibody-producing function of B cells (34–37).
Although STING−/− mice have been shown to be incapable of mounting antibody responses
after immunization with a DNA vaccine encoding ovalbumin (13), the response of B cells to
STING agonists is still unknown. In addition, it is unclear whether STING interacts with
other ER-resident proteins and plays a role in responding to stresses in the ER.
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Materials and Methods
Mice
The XBP-1f/f, CD19Cre/XBP-1f/f, Eμ-TCL1, KaLwRij and the immunodeficient NSG mice
were maintained at our animal facility strictly following the guidelines provided by the
Wistar Institute Committee on Animal Care.
Purification of mouse B cells and Eμ-TCL1 CLL cells
Splenocytes were obtained from mice by mashing the spleens through cell strainers followed
by RBC lysis (Qiagen). Mouse B cells and Eμ-TCL1 CLL cells were purified from mouse
spleens by negative selection using CD43 (Ly48) and Pan-B magnetic beads (Miltenyi
Biotech), respectively, according to the manufacturer’s instructions.

Author Manuscript

Flow cytometric analysis
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Antibodies and reagents

Peripheral blood mononuclear cells (PBMCs) were blocked for 30 minutes using FBS. Cell
surface staining was achieved by incubating cells at 4°C for 30 minutes with the following
anti-mouse antibodies: CD3 (145-2C11; Biolegend), IgM (e-Bioscience), B220 (RA3-6B2;
BD Pharmingen), CD5 (53-7.3; eBioscience), CD138 (281-2; Biolegend), CD19 (1D3; BD
Pharmingen), CD4 (RM4-5; Biolegend) and CD8α (53-6.7; Biolegend). Viability staining
was accomplished using DAPI exclusion during acquisition. Apoptotic cells were detected
by Annexin V-PE/DAPI staining (BD Pharmingen). Acquisition of B, T and CLL cell
populations was performed on a LSRII cytometer (BD Biosciences) harboring a custom
configuration for the Wistar Institute. Cytometry data was analyzed using FlowJo software
version 7.6.1 (Tree Star Inc.).
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Polyhistidine-tagged mouse IRE-1 (a.a. 21–445) and mouse STING (a.a. 139–379) proteins
were expressed and purified from BL21(DE3) bacterial cells by Ni-NTA affinity column
chromatography (Qiagen) followed by size exclusion column chromatography (GE
Healthcare). Polyclonal antibodies against mouse IRE-1 or mouse STING were generated in
rabbits, and affinity-purified against recombinant proteins. Antibodies to phospho-IRF3
(Cell Signaling), IRF3 (Cell Signaling), phospho-STAT1 Y701 (Cell Signaling), IRE-1 (Cell
Signaling), XBP-1 (Cell Signaling), GRP94 (Stressgen), calnexin (Stressgen), caspase 9
(Cell Signaling), cleaved caspase 9 (Cell Signaling), caspase 3 (Cell Signaling), cleaved
caspase 3 (Cell Signaling), caspase 7 (Cell Signaling), cleaved caspase 7 (Cell Signaling),
PARP (Cell Signaling), MCL1 (Cell Signaling), AIP1 (Cell Signaling) cleaved PARP (Cell
Signaling), p97 (Fitzgerald) and actin (Sigma) were obtained commercially. Polyclonal
antibodies against BiP/GRP78, PDI and class I MHC molecules were generated in rabbits.
LPS (Sigma), 9-Oxo-10(9H)-acridineacetic acid (10-carboxymethyl-9-acridanone, CMA)
(Sigma), 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (Sigma), dithiothreitol (DTT)
(Sigma), brefeldin A (BFA) (Cell Signaling), recombinant IFNβ (Biolegend), CpG-1826
oligodeoxynucleotides (TIB-Molbiol), tunicamycin (Enzo Life Sciences), thapsigargin
(Enzo Life Sciences), MG-132 (Enzo Life Sciences), 2′2′-cGAMP (InvivoGen), 2′3′cGAMP (InvivoGen), c-di-UMP (InvivoGen), poly(I:C) (InvivoGen), IL2 (Biolegend), IL4
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(Biolegend) and CD40L (Thermo Fisher) were purchased commercially. Subtilase cytotoxin
(SubAB) was provided by Dr. James C. Paton at the University of Adelaide. We developed
and synthesized the IRE-1 RNase inhibitor, B-I09 (38). 3′3′-cGAMP were chemically
synthesized in house according to the known synthetic route (1,39,40).
Cell culture

Author Manuscript

Mouse B cells, Eμ-TCL1 CLL cells, A20 B-cell lymphoma cells (ATCC) and 5TGM1
multiple myeloma cells (kindly provided by Dr. Lori A. Hazlehurst) were cultured in the
RPMI 1640 media (Gibco) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin G sodium, 100 μg/ml streptomycin sulfate, 1
mM sodium pyruvate, 0.1 mM non-essential amino acids, and 0.1 mM β-mercaptoethanol
(β-ME). 5TGM1 cells were tested for the secretion of immunoglobulin and the surface
expression of plasma cell marker, CD138, every 6 months. Mouse embryonic fibroblasts
(MEFs), IRE-1−/− MEFs, XBP-1−/− MEFs, B16 melanoma (ATCC), Hepa 1–6 hepatoma
(ATCC), LL/2 Lewis lung carcinoma (ATCC) were cultured in Dulbecco’s Modified Eagle’s
Medium (Gibco) with the same supplemental nutrients. All our cell lines are negative for
mycoplasma contamination.
Deletion of the STING gene in 5TGM1 and A20 cells with zinc finger nucleases (ZFN) and
establishment of STING-null 5TGM1 and A20 cells
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ZFN mRNA reagents specific to mouse STING (TMEM173) were designed, assembled and
tested for functionality using CompoZr® fluorescent protein (FP)-linked ZFN technology
(Sigma-Aldrich, CSTZFN). The ZFN target sequence (cut site in lowercase) is:
GGCCTGGTCATACTACATtgggtaCTTGCGGTTGATCTT. One million of A20 or 5TGM1
cells were combined with ZFNs and Nucleofector Solution V (Lonza, VACA-1003) and
nucleofected using the Amaxa Nucleofector I device (Lonza) with program L-013. The
nucleofected cells were allowed to recover for 48 h. FP-expressing cells were collected in a
pool via FACS and a portion was used for genomic DNA purification. STING (TMEM173)
was amplified with JumpStart™ REDTaq® ReadyMix™ Reaction Mix (Sigma-Aldrich,
P0982) with the primer pair FWD 5′-CAAGAGAAGGGCTTTGGACA-3′ and REV 5′GCTCCTGCCTCAAAGATCAC-3′ using the thermal cycle program: 95°C for 5 min; 35
cycles: 95°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec; 72°C for 5 min; and 4°C hold.
The resulting PCR product was denatured, re-annealed, and digested using Surveyor®
Mutation Detection Kit (IDT, 706025) according to manufacturer instructions. Digested
heteroduplexed DNA was resolved on a 10% TBE gel to verify the cleavage of the 326 bp
product into 181 bp and 145 bp fragments (see Supplementary Fig. 5). 5TGM1 STING-ZFN
and A20 STING-ZFN cells were cloned via limited dilution and cultured in the RPMI 1640
media (Gibco) with supplements described above.
Mass Spectrometry
Protein bands were stained with Coomassie Brilliant Blue G-250, excised, reduced,
alkylated, and digested with trypsin (Promega). Reverse phase liquid chromatography
tandem mass spectrometry (LC-MS/MS) analysis was performed by the Wistar Proteomics
Facility using a Q Exactive HF mass spectrometer (Thermo Scientific) coupled with a NanoACQUITY UPLC system (Waters). Eluted peptides were analyzed by the mass spectrometer
Cancer Res. Author manuscript; available in PMC 2017 April 15.
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set to repetitively scan m/z from 400 to 2000 in positive ion mode. The full MS scan was
collected at 70,000 resolution followed by data-dependent MS/MS scans at 17,500
resolution on the 20 most abundant ions exceeding a minimum threshold of 10,000. Peptide
match was set as preferred, exclude isotopes option and charge-state screening were enabled
to reject singly and unassigned charged ions. MS data were analyzed with MaxQuant 1.5.2.8
(Ref: PMID 19029910). MS/MS spectra were searched against the mouse UniProt protein
database using full tryptic specificity with up to two missed cleavages, static
carboxamidomethylation of Cys, and variable oxidation of Met, protein N-terminal
acetylation and phosphorylation on Ser, Thr and Tyr. Modified peptides were required to
have a minimum score of 40. Consensus identification lists were generated with false
discovery rates of 1% at protein, peptide and site levels. MS/MS assignment of
phosphorylated peptides were manually inspected and peaks were labeling using pLabel
(pfind.ict.ac.cn).
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Protein isolation, immunoprecipitation, dephosphorylation and immunoblotting
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Cells were lysed in RIPA buffer (10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% NP-40; 0.5%
sodium deoxycholate; 0.1% SDS; 1 mM EDTA) supplemented with protease inhibitors
(Roche) and phosphatase inhibitors. Protein concentrations were determined by BCA assays
(Pierce). In some experiments, target proteins were immunoprecipitated with antibodies
together with Protein G-agarose beads (Sigma), and bead-bound proteins were
dephosphorylated using calf intestinal alkaline phosphatase (CIP, New England Biolabs) or
lambda protein phosphatase (λPPase, New England Biolabs). Samples were boiled in SDSPAGE sample buffer (62.5 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerol; 0.1%
bromophenol blue) with β-ME and analyzed by SDS-PAGE. Proteins were transferred to
nitrocellulose membranes, blocked in 5% non-fat milk (wt/vol in PBS), and immunoblotted
with indicated primary antibodies and appropriate horseradish peroxidase-conjugated
secondary antibodies. Immunoblots were developed using Western Lighting
Chemiluminescence Reagent (Perkin-Elmer).
Pulse chase experiments, immunoprecipitation and protein deglycosylation

Author Manuscript

Cells were starved in methionine- and cysteine-free media containing dialyzed serum for 1
h, then pulse-labeled with 250 μCi/ml [35S]-methionine and [35S]-cysteine (Perkin-Elmer)
for indicated times. After labeling, cells were incubated in the chase medium containing
unlabeled methionine (2.5 mM) and cysteine (0.5 mM). In some experiments, 3′3′-cGAMP
was added in the chase medium. At the end of each chase interval, cells were lysed in RIPA
buffer containing protease inhibitors. Pre-cleared lysates were incubated with an anti-mouse
STING or anti-class I MHC antibody, together with Protein G-agarose beads. Bead-bound
proteins were eluted using glycoprotein denaturing buffer (0.5% SDS, 40 mM DTT) or
reducing Laemmli SDS-PAGE sample buffer. Enzymatic deglycosylation of proteins was
achieved by denaturation of the immunoprecipitates in glycoprotein denaturing buffer at
95°C for 10 min, followed by addition of sodium citrate (pH 5.5) to a final concentration of
50 mM, and incubated with Endo H (New England Biolabs) at 37°C for 3 h. Alternatively,
sodium phosphate (pH 7.5) and NP-40 were added to the denatured cell lysates to a final
concentration of 50 mM and 1%, respectively, and the mixture was incubated with PNGase
F (New England Biolabs) at 37°C for 3 h. Protein samples were then analyzed by SDSCancer Res. Author manuscript; available in PMC 2017 April 15.
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PAGE and visualized by autoradiography. Densitometric quantification of radioactivity was
performed on a PhosphorImager (Fujifilm BAS-2500) using Image Reader BAS-2500 V1.8
software (Fujifilm) and Multi Gauge V2.2 (Fujifilm) software for analysis.
Reverse transcription and polymerase chain reaction (PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen). Complementary DNA was
synthesized from RNA using Superscript II reverse transcriptase (Invitrogen). The following
sets of primers were used together with Platinum Taq DNA polymerase (Invitrogen) in PCR
to detect the expression of mouse IFNα (CCA CAG GAT CAC TGT GTA CCT GAG A and
CTG ATC ACC TCC CAG GCA CAG); mouse IFNβ (CAT CAA CTA TAA GCA GCT
CCA and TTC AAG TGG AGA GCA GTT GAG) and mouse GAPDH (CTC ATG ACC
ACA GTC CAT GC and CAC ATT GGG GGT AGG AAC AC).
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Immunofluorescence staining and confocal microscopy
2 × 104 ~ 5 × 104 5TGM1 or 5TGM1 STING-ZFN cells were seeded on a coverglass,
treated with 3′3′-cGAMP for indicated times, spun down onto the coverglass (1,200 rpm; 10
minutes), fixed in the fixation solution (acetone : methanol = 4 : 6) at −20 °C for 15 minutes,
and air-dried. Cells were rehydrated with PBS, blocked in 3% BSA (in PBS), and incubated
with rabbit anti-STING and mouse anti-Man2A1 (Mannosidase II; Biolegend) primary
antibodies and subsequently with Alexa 488-conjugated goat anti-rabbit (Invitrogen
Molecular Probes) and Alexa 594-conjugated goat anti-mouse (Life Technologies)
secondary antibodies. The coverglass was mounted on a glass slide and cells were observed
using a Leica TCS SP5 II confocal microscope.
Cell proliferation XTT assays
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Appropriate numbers of cells were suspended in phenol red-free culture media, seeded in
96-well cell culture plates, and treated with STING agonists, TLR ligands or other chemical
compounds. Every 24 hours after the treatment, cells were spun down and proliferation was
assessed by XTT assays (Roche) according to the manufacturer’s instructions. Briefly, 50 μl
XTT labeling reagent, 1 μl electron-coupling reagent and 100 μl phenol red-free culture
media were combined and applied to each well of the 96-well plates. Cells were then
incubated for 4 h in a CO2 incubator to allow for the yellow tetrazolium salt XTT to be
cleaved by mitochondrial dehydrogenases of metabolic active cells to form the orange
formazan dye, which can be quantified at 492 nm using a BioTek Synergy H1 MicroPlate
Reader.
In vivo treatment of mice with 3′3′-cGAMP
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The peripheral blood of Eμ-TCL1 mice was collected by submandibular bleeding. Eμ-TCL1
Mice with high CLL burden were identified by measuring lymphocyte numbers using a
HemaTrue Hematology Analyzer (HESKA) and examining the percentage of CLL cells in
PBMCs. These mice received intraperitoneal injections with 3′3′-cGAMP (10 mg/kg)
dissolved in 20% DMSO in PBS on Days 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18 and 19.
Lymphocyte numbers in their peripheral blood were measured on Days 7, 14 and 21.
KaLwRij mice were intravenously injected with 5 × 106 5TGM1 or 5TGM1 STING-ZFN
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multiple myeloma cells on D0; intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) on
Days 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 17, 18, 19, 20 and 21; and monitored for survival.
Immunodeficient NSG mice were subcutaneously injected with 5 × 106 5TGM1 multiple
myeloma cells on D0; intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) on Days 1, 2,
3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18 and 19; and monitored for the size of tumor and
weight at the indicated times.
Statistics
The Kaplan-Meier analysis was used to evaluate mouse survival data. A p-value of less than
0.05 was considered significant.
Study approval
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All experiments involving the use of mice were performed following protocols approved by
the Institutional Animal Care and Use Committee (IACUC) at the Wistar Institute.

Results
IRE-1 associates with STING

Author Manuscript

To investigate the interacting proteins of IRE-1, we generated several rabbit polyclonal
antibodies against the luminal domain of IRE-1 (a.a. 21~445). Affinity-purified IRE-1
antibodies were used to immunoprecipitate IRE-1 together with its interaction partners in
lipopolysaccharide (LPS)-stimulated wild-type mouse B cells. The immunoprecipitated
protein complex was analyzed on an SDS-PAGE gel. A prominent ~35 kDa protein band coimmunoprecipitated with IRE-1 was excised from the gel (Supplementary Fig. 1A). After ingel proteolytic digestion, the samples were subjected to peptide sequencing with LCMS/MS. STING was identified as an associated protein of IRE-1 (Supplementary Fig. 1B).
We generated rabbit polyclonal antibodies against the cytoplasmic domain of mouse STING
(a.a. 139–379). To confirm that IRE-1 interacts with STING, we performed
immunoprecipitations using anti-IRE-1 or anti-STING antibodies in IRE-1−/− MEFs
(mouse embryonic fibroblasts), 5TGM1 cells (mouse multiple myeloma line expressing high
levels of IRE-1), and A20 cells (mouse B cell lymphoma line expressing low levels of
IRE-1). Proteins immunoprecipitated with the anti-IRE-1 antibody were immunoblotted
with anti-IRE-1 or anti-STING antibodies (Fig. 1, A and B), and those immunoprecipitated
with the anti-STING antibody were also immunoblotted with anti-STING or anti-IRE-1
antibodies (Fig. 1, C–D). The association of IRE-1 and STING was preserved not only in
1% NP-40 buffer but also in stringent RIPA buffer containing 0.1% SDS, 0.5% sodium
deoxycholate, and 1% NP-40.
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3′3′-cGAMP is a potent STING agonist
Purine-containing cyclic dinucleotides 2′2′-cGAMP, 3′3′-cGAMP and 2′3′-cGAMP with
distinct phosphodiester linkages can bind to STING; however, c-di-UMP contains a smaller
pyrimidine base and does not bind to STING (Supplementary Fig. 2, A–D; (8,9)). DMXAA
and CMA are chemical compounds that bind to mouse but not human STING
(Supplementary Fig. 2, E–F; (9,23,24,41,42)). We chemically synthesized 3′3′-cGAMP in
large quantities to support our studies, and its identity and purity are demonstrated by
Cancer Res. Author manuscript; available in PMC 2017 April 15.
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nuclear magnetic resonance and reversed-phase high-performance liquid chromatography,
respectively (Supplementary Fig. 3). We treated MEFs with 3′3′-cGAMP, DMXAA and
CMA, and determined the capability of these compounds in activating phosphorylation of
IRF3, which leads to the production of type I interferons (IFNα and IFNβ) and the
subsequent phosphorylation of STAT1 as a result of interferon-α/β receptor (IFNAR)
activation by IFNα and IFNβ in an autocrine fashion (Fig. 1, E–F). We found that in intact
cells, 3′3′-cGAMP is more efficient than DMXAA in activating STING, as judged by
phosphorylation of STING, IRF3 and STAT1 (Fig. 1E). The phosphorylation of STING was
confirmed by treatments of immunoprecipitated STING with calf intestinal phosphatase
(CIP) or λ protein phosphatase (λPPase) and disappearance of the phosphorylated STING
protein band (Fig. 1G). Activation of STING by 3′3′-cGAMP or DMXAA also causes
STING to degrade (Fig. 1, E–F). Although CMA was shown to bind to STING in a protein
crystal structure (23), it does not activate STING in cells (Fig. 1F). Mouse STING contains
only one potential N-linked glycosylation site (N41) in its luminal domain. We hypothesized
that the binding of 3′3′-cGAMP in the cytoplasmic domain of STING may cause STING to
expose this site for glycosylation. No N-linked glycosylation was detected in our
deglycosylation experiments using endo-H or PNGase F (Supplementary Fig. 4).
The IRE-1/XBP-1 pathway is required for normal STING function
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To assess whether IRE-1 is required for activation of STING, we treated wild-type and
IRE-1−/− MEFs with 3′3′-cGAMP for 0, 2, 4, 8, 12, or 24 h, and detected a significantly
delayed and weaker phosphorylation of STING and IRF3 in IRE-1−/− MEFs (Fig. 2A).
Correspondingly, the production of IFNα and IFNβ decreased significantly (Fig. 2, B–C),
leading to inefficient phosphorylation of STAT1 in IRE-1−/− MEFs (Fig. 2A). Upon 3′3′cGAMP stimulation, STING undergoes phosphorylation and degradation (Figs. 1, E–F and
2A). Thus, we measured the half-life of STING in 3′3-cGAMP-treated cells by pulse chase
experiments (Fig. 2D). STING in 3′3′-cGAMP-stimulated wild-type MEFs has a half-life of
approximately 5 h, but it acquires an approximately 10-h half-life in 3′3′-cGAMP-stimulated
IRE-1−/− MEFs (Fig. 2D), suggesting association with IRE-1 is critical for STING function
and degradation. We examined XBP-1, a transcription factor regulated by the RNase activity
of IRE-1. 3′3′-cGAMP-induced phosphorylation of STING, IRF3 and STAT1 as well as
IFNβ production were similarly compromised in XBP-1−/− MEFs (Fig. 2, E–F). STING is
synthesized in lesser quantity in XBP-1−/− MEFs, and is rapidly degraded upon stimulations
with 3′3′-cGAMP (Fig. 2E). When wild-type and XBP-1−/− MEFs were treated with 3′3′cGAMP for 24 h and continued to culture in fresh media for another 48 h, XBP-1−/− MEFs
was unable to restore the expression levels of STING (Fig. 2G). Despite the significant
reduction of 3′3′-cGAMP-induced activation of STING in IRE-1−/− and XBP-1−/− MEFs,
3′3′-cGAMP does not impact the growth of these cells as well as wild-type MEFs (Fig. 2,
H–I).
B cells respond to STING agonists by undergoing mitochondria-mediated apoptosis
To recapitulate compromised STING activation in XBP-1KO B cells, we treated naïve B
cells purified from XBP-1f/f and CD19Cre/XBP-1f/f mice with 3′3′-cGAMP. Contrary to our
results from MEFs, STING in XBP-1WT and XBP-1KO B cells does not undergo degradation
upon stimulations by 3′3′-cGAMP (Fig. 3A). B cells initiate rapid apoptosis shortly after
Cancer Res. Author manuscript; available in PMC 2017 April 15.
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3′3′-cGAMP stimulations, as judged by cleavage of a caspase substrate, PARP (Fig. 3A).
3′3′-cGAMP but not c-di-UMP induces cytotoxicity in B cells in a dose-dependent fashion
(Fig. 3B), suggesting that cytotoxicity is a result of STING binding (also see below). LPS
and CpG can induce B cell proliferation and differentiation by engaging Toll-like receptor
(TLR) 4 and TLR9, respectively (Fig. 3C). We investigated whether STING agonists have an
impact on LPS- or CpG-induced cell growth. 2′2′-, 2′3′-, and 3′3′-cGAMP may have
different binding affinities to STING (5,9). Co-incubation of 2′2′-cGAMP, 2′3′-cGAMP or
3′3′-cGAMP retards LPS- or CpG-induced B cell proliferation (Fig. 3, D–E). To examine
the impact of STING agonists on antibody-secreting plasma cells, we first incubated purified
naïve B cells in LPS or CpG for 48 h to trigger their differentiation into plasmablasts, and
subsequently treated these cells with 3′3′-cGAMP in a dose-dependent (Fig. 3F) and timedependent (Fig. 3, G–H) manner. Similarly, 3′3′-cGAMP does not induce the degradation of
STING in these plasmablasts, but it triggers mitochondria-dependent apoptosis as evidenced
by the cleavage of caspase 9, caspase 3, caspase 7 and PARP (Fig. 3, F–H). Treatment of
plasmablasts with 3′3′-cGAMP for 24 h turns almost all plasmablasts into Annexin V+/
DAPI+ apoptotic cells (Fig. 3I). 3′3′-cGAMP also potently suppresses IL4- and CD40Linduced B cell growth (Fig. 3J).
STING agonists are cytotoxic to B cell leukemia, lymphoma and multiple myeloma

Author Manuscript

Because STING agonists induced apoptosis in primary B cells and plasmablasts, we
investigated whether these agonists would also be cytotoxic to primary B-cell chronic
lymphocytic leukemia freshly purified from Eμ-TCL1 mice (38,43,44), A20 B-cell
lymphoma and 5TGM1 multiple myeloma. We treated these malignant B cells with 3′3′cGAMP and c-di-UMP. 3′3′-cGAMP but not c-di-UMP was able to induce apoptosis in
malignant B cells (Fig. 4, A–B). When 5TGM1 multiple myeloma cells were treated with
increasing concentrations of 3′3′-cGAMP for 12 h, we clearly detected a dose-dependent
activation of mitochondria-mediated apoptosis, as shown by the decreased expression of
MCL1 and increased cleavage of caspase 9, caspase 3 and PARP (Fig. 4C). Increased
apoptosis of 5TGM1 cells is associated with the increased degradation of IRE-1 and XBP-1
in a dose-dependent manner (Fig. 4C). In time-course experiments where 5TGM1 cells were
treated with 3′3′-cGAMP, we observed time-dependent activation of mitochondria-mediated
apoptosis, accompanied by the time-dependent decreased expression of IRE-1 and increased
expression of AIP1, an IRE-1-associated proapoptotic protein (45) (Fig. 4D).
STING agonists induce apoptosis in malignant B cells through binding to STING

Author Manuscript

To test whether 3′3′-cGAMP-induced apoptosis in malignant B cells is through binding to
STING, we designed specific zinc finger nucleases to disrupt the mouse STING gene in A20
and 5TGM1 cell lines (see Materials and Methods; Supplementary Fig. 5). Our ZFN design
incorporates a GFP reporter to facilitate enrichment of STING-ZFN-positive cells after
Nucleofection by FACS. By limited dilution cloning, we established STING-null A20 (A20
STING-ZFN) and 5TGM1 (5TGM1 STING-ZFN) clones (Fig. 5A). We treated 5TGM1
STING-ZFN and A20 STING-ZFN cells with increasing concentration of 3′3′-cGAMP for a
course of 72 h. Both STING-ZFN cell lines resist to 3′3′-cGAMP-induced apoptosis (Fig. 5,
B–C; Supplementary Fig. 6).
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STING does not degrade efficiently in malignant B cells, but undergoes phosphorylation
and forms aggregates upon stimulations with 3′3′-cGAMP

Author Manuscript

To illustrate the difference between MEFs and malignant B cells in the degradation of
STING upon 3′3′-cGAMP stimulations, we performed pulse chase experiments using wildtype MEFs, IRE-1−/− MEFs, A20 and 5TGM1 cells, and immunoprecipitated STING using
anti-STING antibodies. When compared with wild-type and IRE-1−/− MEFs, A20 and
5TGM1 cells synthesize more STING and are less efficient in degrading it upon 3′3′cGAMP stimulations (Fig. 5D). To compare the phosphorylation status of STING upon 3′3′cGAMP stimulations, we chemically crosslinked anti-mouse STING antibodies to protein
G-Sepharose beads by dimethyl pimelimidate (DMP), used these beads to
immunoprecipitate STING from un-stimulated and 3′3′-cGAMP-stimulated wild-type MEFs
and 5TGM1 cells, and analyze the immunoprecipitates by LC-MS/MS after tryptic
digestion. By extracted ion chromatograms (XIC) analyses, we detected in two independent
experiments that S357 and S365 of STING were phosphorylated in 3′3′-cGAMP-treated
5TGM1 samples, and that S365 of STING was phosphorylated in 3′3′-cGAMP-treated
MEFs (Supplementary Fig. 7, A–B). We did not detect phosphorylation of STING in
untreated samples, or obtain evidence showing that S357 of STING was phosphorylated in
3′3′-cGAMP-treated MEFs. To investigate the intracellular localization of STING in
malignant B cells after stimulations with 3′3′-cGAMP, we demonstrated that our affinitypurified anti-mouse STING antibody is suitable for immunofluorescence staining because
the immunofluorescence signal of STING was observed only in wild-type 5TGM1 but not
5TGM1 STING-ZFN cells (Supplementary Fig. 8). STING forms aggregates in 3′3′cGAMP-stimulated 5TGM1 cells undergoing rapid apoptosis (Fig. 5E, 5C and 4D). These
aggregates colocalized with alpha-mannosidase II (Man2A1) in the ER and Golgi apparatus
(Fig. 5E).
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The production of type I interferons is not responsible for 3′3′-cGAMP-induced apoptosis
in malignant B cells

Author Manuscript

While 5TGM1 STING-ZFN and A20 STING-ZFN cells do not produce IFNα and IFNβ in
response to 3′3′-cGAMP stimulations, both STING-proficient 5TGM1 and A20 cells can
produce IFNα and IFNβ in the first few hours of 3′3′-cGAMP stimulations before they
succumb to death (Fig. 6, A–D). To examine whether type I interferons can account for 3′3′cGAMP-induced apoptosis, we treated 5TGM1 and A20 cells with increasing concentrations
of recombinant IFNβ for 24 h. Even at the non-physiologically high concentration of 200
ng/mL, the 24-h IFNβ treatment accounts for approximately 30% growth inhibition (Fig. 6E)
but not apoptosis, as confirmed by no evidence of caspase 9, caspase 3 and PARP cleavage
(Fig. 6F). This does not account for more than 50% apoptosis in A20 cells and 80%
apoptosis in 5TGM1 cells after treatments with 3′3′-cGAMP for 24 h (Fig. 4A).
Transient activation of the IRE-1/XBP-1 pathway partially rescues B cells from 3′3′cGAMP-induced apoptosis
In light of that the IRE-1/XBP-1 pathway is suppressed in response to 3′3′-cGAMP-induced
apoptosis (Fig. 4, C–D), and that B-cell leukemia, lymphoma and myeloma requires the
IRE-1/XBP-1 pathway for survival (38,44,46,47), we hypothesized that transient activation
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of the IRE-1/XBP-1 pathway might counter 3′3′-cGAMP-induced apoptosis. We chose to
use Brefeldin A (BFA) to activate the IRE-1/XBP-1 pathway, as it induces activation of
IRE-1 and splicing of XBP-1 (Fig. 6G). When comparing 5TGM1 cells treated with 3′3′cGAMP and 3′3′-cGAMP plus BFA, we observed that mitochondria-initiated apoptosis is
significantly abated in 5TGM1 cells treated with 3′3′-cGAMP in combination with BFA
(Fig. 6G). Increased concentrations of BFA is positively correlated with the survival of 3′3′cGAMP-treated 5TGM1 cells (Fig. 6H). To further investigate the role of XBP-1s in 3′3′cGAMP-inuced B cell death, we treated LPS-stimulated XBP-1-proficient and XBP-1deficient B cells with 3′3′-cGAMP, and observed that XBP-1-deficient B cells are more
susceptible to 3′3′-cGAMP-induced apoptosis (Fig. 6I). B-I09 is an inhibitor that potently
suppresses the expression of XBP-1s (38). B-I09 enhances 3′3′-cGAMP-induced apoptosis
in LPS-stimulated wild-type B cells and A20 cells (Supplementary Fig. 9, A–B).
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STING agonists do not induce apoptosis in solid tumors and normal T cells
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To investigate whether 3′3′-cGAMP exerts apoptosis in other types of cancer, we treated
B16 (melanoma), Hepa 1–6 (hepatoma) and LL/2 (Lewis lung cancer) cells with 3′3′cGAMP, DMXAA and CMA. None of the STING agonists influence the growth of these
cells (Fig. 6, J–L), except that there is an approximately 20% growth inhibition in Hepa 1–6
cells after treatment with 3′3′-cGAMP for 24 h (Fig. 6K). To determine whether this was a
result of cytostasis or cytotoxicity, we compared 3′3′-cGAMP-treated 5TGM1 myeloma
cells with 3′3′-cGAMP-treated Hepa 1–6 cells. There is no mitochondria-mediated apoptosis
observed in 3′3′-cGAMP-treated Hepa 1–6 cells (Supplementary Fig. 10A). Similar to
MEFs (Fig. 1, E–F), B16, Hepa 1–6 and LL/2 cells can respond to 3′3′-cGAMP by
phosphorylating and degrading STING, and inducing phosphorylation of IRF3 and STAT1
(Supplementary Fig. 10, B–D). There is also no significant change in the expression levels
of IRE-1 and XBP-1 during the course of 3′3′-cGAMP stimulations (Supplementary Fig. 10,
E–G). Since 3′3′-cGAMP can induce apoptosis in normal B cells, we tested whether it is
also cytotoxic to normal T cells. We purified T cells from wild-type mice, treated them with
3′3′-cGAMP in the presence of IL-2 (to maintain T cell survival in culture), and observed no
apoptosis in 3′3′-cGAMP-treated CD4+ or CD8+ T cells (Supplementary Fig. 11).
STING-deficient cells respond to ER stress inducers by activating the IRE-1/XBP-1
pathway and exhibit normal intracellular transport of class I MHC molecules
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The association of STING with IRE-1 intrigued us to investigate whether STING is involved
in activation of the IRE-1/XBP-1 pathway in response to various ER stress inducers. Each
ER-stress inducer requires a distinct time duration to achieve maximal activation of the ER
stress response. We stimulated 5TGM1 and 5TGM1 STING-ZFN cells for 3 h with
dithiothreitol (DTT, 5 mM), thapsigargin (Tg, 2.5 μM), tunicamycin (Tu, 5 μg/mL), subtilase
cytotoxin (SubAB which cleaves BiP and activates the IRE-1/XBP-1 pathway (48), 100 ng/
mL), B-I09 (an IRE-1/XBP-1 pathway inhibitor (38), 20 μM), Brefeldin A (BFA, 3.5 μM)
and proteasomal inhibitor (MG132, 50 μM). We observed no striking difference in activation
of the IRE-1/XBP-1 pathway and the expression of BiP/GRP78, GRP94, PDI and calnexin
between 5TGM1 and 5TGM1 STING-ZFN cells, except the increased expression of XBP-1s
in thapsigargin- and SubAB-treated 5TGM1 STING-ZFN cells (Supplementary Fig. 12A).
However, this difference in the expression of XBP-1s in response to thapsigargin and SubAB
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was not observed between A20 and A20 STING-ZFN (Supplementary Fig. 12B). In
addition, the 3-h treatments with BFA or MG132 do not induce robust activation of the
IRE-1/XBP-1 pathway in A20 and A20 STING-ZFN cells (Supplementary Fig. 12B). The
quality control of the ER allows only correctly folded and assembled client proteins to exit
the ER and be transported to their final destinations. The class I MHC molecule is one of
such proteins. To examine whether the lack of STING on the ER membrane can disrupt the
quality control function of the ER, we examined the transport of class I MHC molecules in
5TGM1, 5TGM1 STING-ZFN, A20 and A20 STING-ZFN cells by pulse chase experiments
(Supplementary Fig. 12, C–D). Class I MHC molecules in 5TGM1 STING-ZFN and A20
STING-ZFN acquired complex glycans in the Golgi apparatus just like those in the
respective STING-proficient counterparts (Supplementary Fig. 12, C–D), suggesting a
normal ER quality control function in STING-deficient cells.
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Intraperitoneal injections of 3′3′-cGAMP induce leukemic regression in Eμ-TCL1 mice,
prolong the survival of myeloma-grafted KaLwRij mice, and suppress myeloma growth in
NSG mice

Author Manuscript

Since 3′3′-cGAMP is potent in inducing apoptosis in malignant B cells in culture (Fig. 4),
we investigated whether it can similarly elicit apoptosis in B cell malignancies in mice. We
identified CLL-bearing Eμ-TCL1 mice by a complete blood count (CBC). We also analyzed
the ratio of B220+/CD5+ CLL cells to B220+/CD5− precancerous B cells in the gated
CD3−/CD19+/IgM+ population in the peripheral blood of the Eμ-TCL1 mice by flow
cytofluorometry. Only mice that carry >8000 lymphocytes per μL blood and >90% B220+/
CD5+ CLL cells in the CD3−/CD19+/IgM+ population are selected for injection studies
(Fig 7, A–B). We observed a dramatic leukemic regression in CLL-bearing Eμ-TCL1 mice
intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) solubilized in 20% DMSO in PBS,
but not in those mice injected with only the vehicle (Fig. 7B). By performing
immunohistochemcial staining of cleaved caspase 3, we showed that 3′3′-cGAMP induces
apoptosis in the spleens of 3′3′-cGAMP-injected Eμ-TCL1 mice (Fig. 7C).
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To investigate whether the lack of STING can alter malignant phenotypes of 5TGM1 cells in
vivo, we injected intravenously 5 × 106 5TGM1 or 5TGM1 STING-ZFN cells back to
KaLwRij mice (Fig. 7D). No significant difference in survival was observed between mice
injected with 5TGM1 and 5TGM1 STING-ZFN cells (Fig 7D). Some 5TGM1-grafted and
5TGM1 STING-ZFN-grafted mice were intraperitoneally injected with 3′3′-cGAMP (10
mg/kg) daily for the first 5 days of each of the first three week. Injections with 3′3′-cGAMP
significantly prolong the survival of 5TGM1-grafted mice (Fig. 7D). We also observed
increased survival of 5TGM1 STING-ZFN-grafted mice (Fig. 7D), supporting a role of 3′3′GAMP in boosting an anti-tumor immune response (16,17). To highlight the direct effect of
3′3′-cGAMP in targeting malignant B cells in vivo without the help of a functional immune
system, we grafted immunodeficient NSG mice with 5TGM1 cells subcutaneously, and
showed that injections with 3′3′-cGAMP can suppress the growth of multiple myeloma
without the presence of T, B or natural killer cells (Fig. 7E). We confirmed that myeloma
cells remain in the tumor injection site, and do not migrate to bone marrow, peripheral blood
and spleen after 3′3′-cGAMP injections (Supplementary Fig. 13). Injections with 3′3′cGAMP also does not cause NSG mice to lose weight (Fig. 7F).

Cancer Res. Author manuscript; available in PMC 2017 April 15.

Tang et al.

Page 13

Author Manuscript

Discussion
In IRE-1−/− and XBP-1−/− MEFs, STING agonists elicit compromised phosphorylation of
STING and IRF3, reduced production of type I interferons, and decreased phosphorylation
of STAT1 (Fig. 2), suggesting that the normal function of STING depends on the IRE-1/
XBP-1 pathway of the ER stress response. Together with the data showing that the IRE-1/
XBP-1 pathway can be activated normally in STING-ZFN cells by ER stress inducers
(Supplementary Fig. 12, A–B), we propose that the IRE-1/XBP-1 pathway is downstream of
STING.
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STING agonists induce phosphorylation of STING and IRF3, leading to the production of
type I interferons and phosphorylation of STAT1 in MEFs, melanoma, hepatoma and Lewis
lung cancer cells (Figs. 1E, 1F, 1G, 2A, 2B, 2C, 2E, 2F, and Supplementary Fig. 10, B–D).
Continuous incubation with these agonists exerts little impact on the growth of these cells
(Figs. 2H, 2I, 6J, 6K and 6L). Although STING agonists can also trigger malignant B cells
to produce type I interferons shortly after stimulations (Fig. 6, A–D), continuous incubation
induces normal and malignant B cells to undergo rapid apoptosis (Figs. 3, 4 and 5C, and
Supplementary Fig. 6). STING agonist-induced apoptosis is clearly mediated by STING
because STING-ZFN cells do not undergo such apoptosis (Fig. 5, B–C and Supplementary
Fig. 6). How does STING mediate the production of type I interferons in MEFs, melanoma,
hepatoma and Lewis lung cancer cells, but apoptosis in normal and malignant B cells?
Different from MEFs, melanoma, hepatoma and Lewis lung cancer cells, normal and
malignant B cells are incapable of degrading STING efficiently after stimulations by STING
agonists (Figs. 3A, 3G, 3H, 3F, 4C, 5C, 5D, and 6G, and Supplementary Fig. 6). The
prolonged existence of agonist-bound STING may engage activation of apoptotic
machineries through protein complex formation in the ER or Golgi apparatus (Fig. 5E).
Upon 3′3′-cGAMP stimulations, IRE-1−/− MEFs are also less capable in degrading STING
(Figs. 2D and 5D), but they do not undergo apoptosis like B cells even after prolonged
treatment (Fig. 2H). We hypothesize that such a difference may be attributed to (1) the
intrinsic lower expression levels of STING in MEFs (Fig. 5D), (2) the different
phosphorylation status of STING in MEFs, and (3) the lack of B-cell-specific partner
proteins in MEFs to allow for the formation of protein complexes that can initiate apoptosis.
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Recently, in vitro treatment of 2′3′-cGAMP was shown to upregulate the surface expression
of CD86 and increase proliferative activity in B cells purified from the mouse spleen (49). In
this experiment, B cells were pulse-treated for 30 min with 2′3′-cGAMP (30 μM) dissolved
in the permeabilization solution containing digitonin, washed twice with RPMI-1640
complete medium, and cultured in the presence of 0.6 μM 2′3′-cGAMP for 2 days before
analysis. Our data suggest that STING agonists exert distinct effects on different cell types,
and that continuous incubation with STING agonists induces normal and malignant B cells
to die rapidly. While the expression levels of IRE-1 and XBP-1 stay constant in response to
STING agonists in non-hematopoietic cells (Figs. 2A and 2E, and Supplementary Fig. 10,
E–G), STING agonist-induced apoptosis leads to the significant degradation of IRE-1 and
XBP-1s in normal and malignant B cells (Figs. 4C, 4D and 6G, and Supplementary Fig.
9A). BFA blocks vesicular transport between the ER to the Golgi apparatus, causes the ER
stress, and activates the IRE-1/XBP-1 pathway. Transient activation of the IRE-1/XBP-1
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pathway using BFA attenuates activation of apoptosis and increases the survival of STING
agonist-treated malignant B cells (Fig. 6, G–H). Upon activation by the agonists, STING
needs to be transported from the ER to the Golgi apparatus for phosphorylation. Thus, we
observed decreased phosphorylation of STING in malignant B cells treated with BFA (Fig.
6G). To further support our hypothesis that activation of the pro-survival IRE-1/XBP-1
pathway can protect B cells from STING agonist-induced apoptosis, we showed that
deletion of the XBP-1 gene and chemical inhibition of XBP-1s can aggrandize the growth
suppression effect of STING agonists in normal and malignant B cells (Fig. 6I and
Supplementary Fig. 9).
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STING agonists have been proposed to be used as adjuvants for vaccinations and cancer
therapy (14–17,50). Such applications rely on the capability of STING agonists in triggering
the production of type I interferons. Type I interferons subsequently bind to IFNAR and
activate the JAK-STAT signaling pathway to allow for the increased expression of cytokines
such as TNFα, IL-1β, IL6 and CXCL10. Type I interferons together with these cytokines
boost the immune system by promoting proliferation, differentiation, survival and
mobilization of a number of immune cells. Our data show that STING agonists are cytotoxic
to mouse B cells (Fig. 3), thus indicating their use as adjuvants to boost antibody production
may not be feasible. Nevertheless, the specific cytotoxicity of STING agonists to malignant
mouse B cells (Figs. 4 and 7) suggests the potential therapeutic use of STING agonists in
treating B cell malignancies in addition to their immunomodulatory activity which is also
against cancer (Fig. 7). Unmet medical needs still exist for the treatment of relapsed and
refractory B cell-derived malignancies such as chronic lymphocytic leukemia, mantle cell
lymphoma and multiple myeloma. The disadvantage of using STING agonists in treating B
cell malignancies at least includes the collateral damage to normal B cells. Rituximab (an
anti-CD20 monoclonal antibody) prescribed for the treatment of various B cell malignancies
destroys both normal and malignant B cells. However, intravenous immunoglobulin (IVIG)
can be administered during the treatment period to maintain adequate levels of antibodies to
prevent infections.
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Figure 1. IRE-1 associates with STING, and 3′3′-cGAMP is a potent agonist of STING

Author Manuscript

IRE-1 −/− MEFs, 5TGM1 cells, and A20 cells were lysed in RIPA buffer or lysis buffer
containing 1% NP-40. Immunoprecipitations were performed with anti-IRE-1 (A–B) or antiSTING (C–D) antibodies. Proteins immunoprecipitated with anti-IRE-1 were
immunoblotted with an anti-IRE-1 (A) or anti-STING (B) antibody. Proteins
immunoprecipitated with anti-STING antibodies were immunoblotted with an anti-STING
(C) or anti-IRE-1 (D) antibody. (E–F) 3′3′-cGAMP activates STING more efficiently than
DMXAA (E) and CMA (F). WT MEFs were treated with 20 μM 3′3′-cGAMP, 20 μM
DMXAA, or 20 μM CMA for indicated times and lysed for analysis of indicated proteins by
immunoblots. AAA ATPase (p97) and actin serve as loading controls. (G) WT MEFs were
untreated or treated with 20 μM 3′3′-cGAMP for 4 h. Cell lysates were immunoprecipitated
by an anti-STING antibody. Bead-bound immunoprecipitated proteins were further treated
with calf intestinal phosphatase (CIP) or λ protein phosphatase (λ PPase) for 3 h, and
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immunoblotted with an anti-STING antibody. Data in this figure are representative of three
independent experiments. **: immunoglobulin heavy chain; *: immunoglobulin light chain.
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Figure 2. The IRE-1/XBP-1 pathway is critical for normal STING function

(A) WT and IRE-1−/− MEFs were treated with 20 μM 3′3′-cGAMP for indicated times and
then lysed for analysis of indicated proteins by immunoblots. Data are representative of
three independent experiments. (B–C) WT and IRE-1−/− MEFs were treated with 20 μM
3′3′-cGAMP for indicated times, and lysed for purification of total RNA and synthesis of
cDNA. The mRNA expression levels of IFNα and IFNβ were measured by real-time
quantitative PCR (RT-qPCR), performed in triplicate for each sample (n=3). Data from WT
and IRE-1−/− MEFs were normalized to GAPDH (as 1) and shown as mean ± SD. Data are
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representative of three independent experiments. (D) WT and IRE-1−/− MEFs were
radiolabeled for 4 h and chased for indicated times in the presence of 20 μM 3′3′-cGAMP.
Lysates were immunoprecipitated with an anti-STING antibody, and analyzed by SDSPAGE and autoradiography. The signal of STING was quantified by densitometry. This
experiment was repeated for 3 times with similar results. (E) WT and XBP-1−/− MEFs were
treated with 20 μM 3′3′-cGAMP for indicated times and lysed for analysis of indicated
proteins by immunoblots. Data are representative of three independent experiments. (F) WT
and XBP-1−/− MEFs treated with 20 μM 3′3′-cGAMP for indicated times were analyzed for
the expression of IFNβ by RT-qPCR. Data are representative of three independent
experiments. (G) WT and XBP-1−/− MEFs were treated with 20 μM 3′3′-cGAMP for 24, 48
or 72 h; some cells were treated with 20 μM 3′3′-cGAMP for 24 h, washed with fresh media
twice, and incubated in fresh media for additional 24 or 48 h. Cells were lysed for analysis
of indicated proteins by immunoblots. Results are representative of three independent
experiments. (H–I) WT and IRE-1−/−MEFs (H) or WT and XBP-1−/− MEFs (I) were
untreated or treated with 3′3′-cGAMP (20 μM) for a course of 3 days, and subjected to XTT
assays at the end of each day. Percentages of growth were determined by comparing treated
groups with untreated control groups. Each data point derived from four independent groups
receiving exactly the same treatment was plotted as mean ± SD. Results are representative of
three independent experiments.
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Figure 3. STING agonists induce mitochondria-initiated apoptosis in B cells

(A) Freshly purified B cells from XBP-1WT and XBP-1KO spleens were treated with 20 μM
3′3′-cGAMP, and lysed for analysis by immunoblots for indicated proteins. Results shown in
each immunoblot are representative of three independent experiments. For each experiment,
naïve XBP-1WT and XBP-1KO B cells were purified and pooled from at least two mouse
spleens. (B) Naïve B cells purified from mouse spleens were untreated or treated with c-diUMP or 3′3′-cGAMP at indicated concentrations for 24 h, and subjected to XTT assays.
Percentages of growth were determined by comparing treated with untreated groups. Each
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data point derived from four independent groups receiving exactly the same treatment was
plotted as mean ± SD. Data are representative of three independent experiments. (C) Naïve
B cells were cultured in the presence of LPS (20 μg/ml), CpG-1826 (0.5 μM) or poly(I;C)
(10 μg/ml) for 2 days. At the end of each day, cells were subjected to XTT assays.
Percentages of growth were determined by comparing colorimetric reading on Day 1 and
Day 2 with that on Day 0. Each data point derived from four independent groups receiving
the same treatment was plotted as mean ± SD. Results shown are representative of three
independent experiments. (D–E) Naïve B cells were cultured for 3 days in the presence of
LPS (20 μg/ml) alone or LPS plus 15 μM 2′2′-cGAMP, 2′3′-cGAMP or 3′3′-cGAMP (D).
Similarly, naïve B cells were cultured in the presence of CpG-1826 (0.5 μM) alone or
CpG-1826 plus three types of cGAMP (15 μM) (E). At the end of each day, cells were
subjected to XTT assays. Percentages of growth were determined by comparing cells treated
with LPS plus cGAMP (or CpG-1826 plus cGAMP) with those treated with LPS (or
CpG-1826) alone. Each data point derived from four independent groups receiving the same
treatment was plotted as mean ± SD. Data are representative of three independent
experiments. (F) Naïve B cells were stimulated for 2 days in the presence of LPS to allow
for differentiation into plasmablasts. Plasmablasts were subsequently treated with indicated
concentrations of 3′3′-cGAMP in the presence of LPS for additional 12 h, and lysed for
analysis of indicated proteins by immunoblots. Data are representative of three independent
experiments. (G–H) Naïve B cells were stimulated for 2 days in the presence of LPS (G) or
CpG-1826 (H) to allow for differentiation into plasmablasts, which were subsequently
treated with 15 μM 3′3′-cGAMP in the presence of LPS or CpG-1826 for indicated times.
Lysates were analyzed for indicated proteins by immunoblots. Data are representative of
three independent experiments. (I) B cells stimulated with LPS for 2 days were untreated or
treated with 15 μM 3′3′-cGAMP for additional 24 h, stained with Annexin V-PE and DAPI,
and analyzed by flow cytofluorometry. Data are representative of three independent
experiments. (J) Naïve B cells were cultured in the presence of IL4 (100 ng/ml) plus CD40L
(50 ng/ml) together with 3′3′-cGAMP at indicated concentrations for 3 days. At the end of
each day, cells were subjected to XTT assays. Percentages of growth were determined by
comparing colorimetric reading on each day with that on Day 0. Each data point derived
from four independent groups receiving the same treatment was plotted as mean ± SD.
Results shown are representative of three independent experiments.
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Figure 4. STING agonists induce mitochondria-initiated apoptosis in B cell malignancies

(A) Eμ-TCL1 CLL, A20 B-cell lymphoma, and 5TGM1 multiple myeloma cells were
untreated or treated with c-di-UMP (15 μM) or 3′3′-cGAMP (15 μM) for 3 days, and
subjected to XTT assays at the end of each day. Percentages of growth were determined by
comparing treated with untreated groups. Each data point derived from four independent
groups receiving exactly the same treatment was plotted as mean ± SD. Results are
representative of three independent experiments. (B) 5TGM1 cells were cultured for 24 h in
the presence of 15 μM c-di-UMP or 3′3′-cGAMP, and lysed for analysis of indicated

Cancer Res. Author manuscript; available in PMC 2017 April 15.

Tang et al.

Page 25

Author Manuscript

proteins by immunoblots. (C) 5TGM1 cells were cultured for 12 h in the presence of 3′3′cGAMP at indicated concentrations, and lysed for analysis of indicated proteins by
immunoblots. (D) 5TGM1 cells were cultured in the presence of 15 μM 3′3′-cGAMP for
indicated times, and lysed for analysis of indicated proteins by immunoblots. Data shown in
immunoblots in this figure are representative of three independent experiments.
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Figure 5. STING-null malignant B cells are resistant to 3′3′-cGAMP-induced apoptosis, possibly
resulted from the slow degradation and aggregations of STING

(A) A20, A20 STING-ZFN, 5TGM1 and 5TGM1 STING-ZFN cells were lysed for analysis
of the expression of STING and p97 by immunoblots. Data are representative of three
independent experiments. (B) A20, A20 STING-ZFN, 5TGM1 and 5TGM1 STING-ZFN
cells were untreated or treated for 72 h with 3′3′-cGAMP at indicated concentrations, and
subjected to XTT assays. Percentages of growth were determined by comparing treated with
untreated groups. Each data point derived from four independent groups receiving exactly
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the same treatment was plotted as mean ± SD. Results are representative of three
independent experiments. (C) 5TGM1 and 5TGM1 STING-ZFN cells were treated with 20
μM 3′3′-cGAMP for indicated times and lysed for analysis of indicated proteins by
immunoblots. Data are representative of three independent experiments. (D) Wild-type
MEFs, IRE-1−/− MEFs, A20 lymphoma and 5TGM1 myeloma cells were radiolabeled for
12 h, and chased for indicated times in the presence of 20 μM 3′3′-cGAMP. Lysates of equal
radioactive counts from each sample were immunoprecipitated with an anti-STING
antibody, and analyzed by SDS-PAGE and autoradiography. The signal of STING was
quantified by densitometry, and data were plotted. This experiment was repeated for 3 times
with similar results. (E) 5TGM1 cells were untreated or treated with 20 μM 3′3′-cGAMP for
8h, co-immunostained with anti-STING and anti-Man2A1 antibodies, and analyzed by
confocal microscopy. Scale bar: 10 μm.
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Figure 6. The IRE-1/XBP-1 pathway but not type I interferon is responsible for 3′3′-cGAMPinduced apoptosis; STING agonists do not inhibit the growth of melanoma, hepatoma, and Lewis
lung cancer cells

(A–D) 5TGM1 and 5TGM1 STING-ZFN cells (A–B) or A20 and A20 STING-ZFN cells
(C–D) were untreated or treated with 20 μM 3′3′-cGAMP for 4 h. Cells were lysed for RNA
extraction and analyzed by RT-qPCR for the expression of IFNα and IFNβ. Data were
normalized to GAPDH and shown as mean ± SD. Data are representative of three
independent experiments. (E) 5TGM1 and A20 cells were untreated or treated with IFNβ of
indicated concentrations for 24 h, and subjected to XTT assays. Percentages of growth were
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determined by comparing treated with untreated groups. Each data point derived from four
independent groups receiving exactly the same treatment was plotted as mean ± SD. Data
are representative of three independent experiments. (F) 5TGM1 and A20 cells were treated
with 20 μM 3′3′-cGAMP or 100 ng/mL IFNβ for 24 h, and lysed for analysis of indicated
proteins by immunoblots. (G) 5TGM1 cells were treated with 20 μM 3′3′-cGAMP or 20 μM
3′3′-cGAMP plus 3.5 μM BFA for indicated times, and lysed for analysis of indicated
proteins by immunoblots. Immunoblot data are representative of three independent
experiments. (H) 5TGM1 cells were untreated or treated with 20 μM 3′3′-cGAMP or 20 μM
3′3′-cGAMP plus BFA of increasing concentrations (0, 0.5, 1 and 3 μM) for 24 h, and
subjected to XTT assays. Percentages of growth were determined by comparing treated with
untreated groups. Fold increase in survival was determined by comparing cells treated with
3′3′-cGAMP plus 0.5, 1 or 3 μM BFA with those treated with 3′3′-cGAMP plus 0 μM BFA
(as 1). Each data point derived from four independent groups receiving exactly the same
treatment was plotted as mean ± SD. Data are representative of three independent
experiments. (I) Two-day LPS-stimulated XBP-1-proficient and XBP-1-deficient B cells
were untreated or treated with 3′3′-cGAMP at indicated concentrations for 24 h, and
subjected to XTT assays. Percentages of growth were determined by comparing treated with
untreated groups. Each data point derived from four independent groups receiving exactly
the same treatment was plotted as mean ± SD. Data are representative of three independent
experiments. (J–L) B16 melanoma (J), Hepa 1–6 hepatoma (K), or LL/2 Lewis lung cancer
(L) cells were untreated or treated with 3′3′-cGAMP (20 μM), DMXAA (20 μM) or CMA
(20 μM) for 3 days, and subjected to XTT assays at the end of each day. Percentages of
growth were determined by comparing treated groups with untreated groups. Each data point
derived from four independent groups receiving exactly the same treatment was plotted as
mean ± SD. Data are representative of three independent experiments.
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Figure 7. Intraperitoneal injections of 3′3′-cGAMP lead to leukemic regression in CLL-bearing
Eμ-TCL1 mice and prolong the survival of KaLwRij mice grafted with multiple myeloma

(A) PBMCs isolated from 2 representative CLL-bearing Eμ-TCL1 mice were stained with
CD3-APC-Cy7, IgM-PE-Cy7, B220-FITC, CD5-APC and DAPI. Gated live CD3−/IgM+ B
cell populations were analyzed for the expression of B220 and CD5. (B) CLL-bearing EμTCL1 mice were injected with vehicle (20% DMSO in PBS, n=9) or 3′3′-cGAMP (10
mg/kg, n=10) daily for the first 5 days in a week for a period of three weeks. Each week,
blood was collected by submandibular bleeding to measure lymphocyte numbers using a

Cancer Res. Author manuscript; available in PMC 2017 April 15.

Tang et al.

Page 31

Author Manuscript
Author Manuscript

HemaTrue Hematology Analyzer (HESKA), and the data were plotted as mean ± SEM. * pvalue < 0.05. NS: non-significant. (C) Paraffin-embedded sections of spleens from Eμ-TCL1
mice receiving three weeks of injections with vehicle or 3′3′-cGAMP (10 mg/kg) were
immunohistochemically stained with an anti-cleaved caspase 3 antibody, developed using
DAB (brown/yellow), and counterstained with hematoxylin. Scale bar: 60 μm. (D) 5TGM1
or 5TGM1 STING-ZFN cells (5 × 106) were intravenously injected into KaLwRij mice (8
mice each group). Half of the 5TGM1-grafted and 5TGM1 STING-ZFN-grafted mice were
intraperitoneally injected with 3′3′-cGAMP (10 mg/kg) daily on the first 5 days of each of
the three weeks, and subjected to Kaplan-Meier survival analysis. * p-value < 0.05. NS: nonsignificant. (E–F) 5TGM1 cells (5 × 106) were subcutaneously injected into
immunodeficient NSG mice (n=10) on Day 0. Five 5TGM1-grafted NSG mice were
intraperitoneally injected with the vehicle (20% DMSO in PBS), and the other five with 3′3′cGAMP (10 mg/kg). A single injection occurs daily on the first 5 days of each of the first
three weeks. No injection but data recording was performed on Day 22 and Day 23. (E)
Tumor volume was plotted as mean ± SD. (F) Body weight were compared with the weight
recorded on Day 1 (100%), and plotted as mean ± SD.
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